Phase 2b Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight
Latest Information Update: 18 Apr 2026
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 19 Mar 2026 Status changed from not yet recruiting to recruiting.
- 04 Mar 2026 New trial record